Virtual Library
Start Your Search
Jiewei Liu
Author of
-
+
P14 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Immuno-Biology (ID 153)
- Event: WCLC 2020
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P14.01 - Impact of Stimulator of Interferon Genes (STING) Signaling on the Tumor Immune Microenvironment in Lung Adenocarcinoma (ID 872)
00:00 - 00:00 | Presenting Author(s): Jiewei Liu
- Abstract
Introduction
Lung adenocarcinoma (LUAD) is a major public health issue. Although immune checkpoint inhibitors have been incorporated into frontline therapy strategies for LUAD, clinical responses remain limited. Using data from The Cancer Genome Atlas database, we assessed the role of stimulator of interferon genes (STING) signaling on the tumor immune microenvironment to explore promising therapeutic strategies for LUAD.
Methods
The correlation between STING signaling, TME, and the overall survival of patients with LUAD was analysed utilizing data downloaded from The Cancer Genome Atlas database. The SsGSEA, CIBERSORT, and ESTIMATE algorithms were applied, and gene set enrichment analysis (GSEA) was conducted to screen Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathways between patients with LUAD expressing low and high levels of STING.
Results
High STING signaling was associated with increased levels of immunoregulatory and effector molecules, cytokines, and activated CD4/CD8 T cells. GSEA revealed that the high STING group was mainly enriched in GO terms and KEGG pathways related to the immune response. Additionally, both STING signaling and activated CD8+ T cells were positively related to overall survival.
Conclusion
Stimulation of the STING signaling pathway within the TME may be useful as a novel immunotherapeutic strategy for LUAD, indicating combination therapy with STING agonists and immune checkpoint inhibitors.
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR (ID 253)
- Event: WCLC 2020
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P76.92 - TKI and Intrathoracic Perfusion in First-line Stage IV Lung Adenocarcinoma with EGFR Mutation and Malignant Pleural Effusion (ID 3687)
00:00 - 00:00 | Author(s): Jiewei Liu
- Abstract
Introduction
Malignant pleural effusion(MPE) is one of the most common complications in advanced lung cancer which predicts worse prognosis. Advanced lung adenocarcinoma with EGFR sensitive mutation have been proved to be sensitive to tyrosine kinase inhibitor(TKI) treatment. However, TKI seems not so efficient in controlling MPE, thus significantly shorten patients’ survival. Here we compared prognosis of TKI treatment with/without intrathoracic perfusion in patients with treatment-naive stage IV lung adenocarcinoma with EGFR mutation and MPE.
Methods
Patients who were diagnosed with previously untreated stage IV lung adenocarcinoma with MPE were identified, in which only with EGFR sensitive mutation were selected, in Lung Cancer Center and Thoracic Oncology department, West China Hospital of Sichuan University from February 2012 to October 2018. The study population was divided into two cohorts with respect to received treatment, patients with TKI treatment alone(TKIs) or TKI along with concomitant intrathoracic perfusion(TKIs+ITP). The follow-up was performed via telephone and overall survival(OS) was calculated. The difference of efficacy of TKIs and TKIs+ITP was identified via Kaplan-Meier method. A P-value of less than 0.05 was viewed as a statistically significant level.
Results
A total of 53 patients were included in the study with an median age of 51 years(range, 33-81years), in which 23(43.4%) were males, 27(50.9%) were stage IVA, and 26(49.1%) were stage IVB. Among total population, 22(41.5%) were found in the left thoracic cavity, 28(52.8%) were found in the right, and 3(5.7%) were found in the bilateral. As for genetic mutation types, 34(64.2%) of them were found 19-del mutation, 20(37.7%) were found L858R mutation, and 7(13.2%) were T790M mutation. Eighteen patients(34.0%) received intrathoracic perfusion of platinum-based chemotherapy, in which 8(15.1%) received additional interleukin-2 or antiangiogenic agents. The median OS was 31 months(range, 2-84months) and 66 months(range, 3-90months) for TKIs and TKIs+ITP, respectively(P=0.039; Figure 1).
Figure 1 Kaplan-Meier curves comparing the treatment in overall survival(P=0.039) in patients with tyrosine kinase inhibitor treatment(TKIs) alone and TKI along with concomitant intrathoracic perfusion(TKIs+ITP).
Conclusion
Intrathoracic perfusion combined with TKI treatment could improve the prognosis of stage IV lung adenocarcinoma with EGFR mutation, compared to TKI treatment alone. Overall response rate(ORR), progression free survival(PFS) and subgroup analysis concerning different genetic mutation types will be carried out subsequently.
